Effect on Cognitive Function of a Treatment With Aripiprazole

A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00329810

Enrollment

500

Registered

2006-05-25

Start date

2005-03-31

Completion date

2006-03-31

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Interventions

DRUGAripiprazole

Tablets, oral, 15 mg, once daily, 12 weeks.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Schizophrenia * score of 2-6 in the CGI-S scale at basline * ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment

Exclusion criteria

* women of child bearing potential * women pregnant or breast feeding * patients with a score of 0,-1 or 7 * substance use

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression scale at endpoint	—

Secondary

Measure	Time frame
Change in Clinical Global Impression scale and cognition scales at endpoint	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026